$0.034
-0.021 (-61.36%)At close
- High
- 0.080
- Open
- 0.080
- VWAP
- 0.05
- Vol
- 67.48M
- Mkt Cap
- 27.15M
- Low
- 0.031
- Amount
- 3.26M
- EV/EBITDA, TTM
- -2.10
Accelerate Diagnostics, Inc. is an in-vitro diagnostics company. The Company is engaged in providing solutions that improve patient outcomes through the diagnosis of serious infections. Its in-vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. It detects and identifies pathogens directly from a single patient sample followed by antimicrobial susceptibility testing based on the identification results. The Accelerate Pheno system features walk-away automation and consists of a fixed instrument and single-use test kit. The Accelerate PhenoTest BC Kit, in conjunction with other clinical and laboratory findings, in the diagnosis of bacteremia and fungemia, both life-threatening conditions with high morbidity and mortality risk.
Analyst Ratings (4)
Craig-Hallum
$1
2024-04-01
Craig-Hallum
2024-04-01
Price Target
$1
Craig-Hallum
$50
2022-03-09
Craig-Hallum
2022-03-09
Price Target
$50
BTIG
—
2020-10-08
BTIG
2020-10-08
Price Target
—
JP Morgan
$160
2019-09-27
JP Morgan
2019-09-27
Price Target
$160
JP Morgan
$160
2018-11-07
JP Morgan
2018-11-07
Price Target
$160
Valuation Metrics
Events Timeline
News
4.505-14BenzingaNasdaq Gains Over 100 Points; Sony Group Posts Upbeat Earnings
9.505-14BenzingaWhy Everus Construction Group Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
4.505-13BenzingaUS Stocks Likely To Open Lower After A Strong Rally: 'Lows Are Likely In And Better Times Are Coming,' Says Expert
2.005-13BenzingaWhy Coinbase Global Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket
9.005-08NewsfilterAccelerate Diagnostics Files for Chapter 11 Protection and Agrees to Terms to Sell Substantially All Assets
AXDX FAQ — answered by Alphio AI
Accelerate Diagnostics, Inc. is an in-vitro diagnostics company. The Company is engaged in providing solutions that improve patient outcomes through the diagnosis of serious infections. Its in-vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. It detects and identifies pathogens directly from a single patient sample followed by antimicrobial susceptibility testing based on the identification results. The Accelerate Pheno system features walk-away automation and consists of a fixed instrument and single-use test kit. The Accelerate PhenoTest BC Kit, in conjunction with other clinical and laboratory findings, in the diagnosis of bacteremia and fungemia, both life-threatening conditions with high morbidity and mortality risk. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).
4 analysts cover AXDX: 4 rate it Buy, 0 Hold and 0 Sell.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.